Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study
Open Access
- 1 August 2015
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 100 (8) , e311-e314
Abstract
While fludarabine-based regimens are a standard for treatment of chronic lymphocytic leukemia (CLL), patients who become refractory to fludarabine have had low response rates with salvage therapy and poor survival outcomes.[1][1]–[3][2] We reported that ofatumumab, a human monoclonal antibody thatKeywords
This publication has 14 references indexed in Scilit:
- Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic regionLeukemia & Lymphoma, 2014
- Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritisThe Journal of Clinical Pharmacology, 2014
- Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 studyBritish Journal of Haematology, 2010
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2010
- Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome VariablesJournal of Clinical Oncology, 2008
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialBlood, 2008
- The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathyLeukemia & Lymphoma, 2007
- The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20The Journal of Immunology, 2006
- Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 2002
- Analysis of survival by tumor response.Journal of Clinical Oncology, 1983